Celesq® Programs

Dura Pharmaceuticals Two Years Later: The Continuing Struggle to Define Loss Causation in Securities Fraud Actions

Expired
Program Number
1732
Program Date
2007-08-07

Tom Gorman reviews the Supreme Court's decision in Dura Pharmaceuticals, which defined loss causation in securities damage actions under Section 10(b) and Rule 10b-5 of the Exchange Act, and focuses on recent key circuit and district court decisions.

Available in States

  • Arizona
  • California
  • Colorado Eligible
  • Georgia
  • Missouri
  • New York
  • Texas Self Study
  • New Jersey Eligible

Program Categories

  • California Participatory MCLE Programs
  • Corporate and Commercial Law
  • In-House Counsel
  • Litigation & Litigation Skills
  • New York Accredited
  • Securities & Investing